Intra-assay reliability and robustness of QuantiFERON®-TB gold in-tube test in Zambia

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 7, 2010, Pages 828-833

  Shanaube, Kwama ^a   De Haas, P ^a,b   Schaap, A ^a,b   Moyo, M ^a   Kosloff, B ^a,b   Devendra, A ^b   Raby, E ^b   Godfrey Faussett, P ^a   Ayles, H ^a,b  

^a UNIVERSITY OF ZAMBIA   (Zambia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

HIV; QuantiFERON TB gold in tube; Reliability; Tuberculosis; Zambia

Indexed keywords

BACTERIAL ANTIGEN; GAMMA INTERFERON;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GOLD STANDARD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INCUBATION TIME; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; POWER SUPPLY; PRIORITY JOURNAL; QUANTIFERON TB GOLD IN TUBE TEST; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; SCREENING TEST; SPUTUM SMEAR; STORAGE TEMPERATURE; ZAMBIA; COMPLICATION; LABORATORY DIAGNOSIS; PROCEDURES; REPRODUCIBILITY; TEMPERATURE; TIME; TUBERCULOSIS;

ADULT; ELECTRIC POWER SUPPLIES; FEMALE; HIV INFECTIONS; HUMANS; INTERFERON-GAMMA; MALE; REPRODUCIBILITY OF RESULTS; SPECIMEN HANDLING; TEMPERATURE; TIME FACTORS; TUBERCULOSIS; ZAMBIA;

EID: 77953634739     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. National Institute for Health and Clinical Excellence. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control 2006. Clinical Guideline 33. London, UK: NICE, 2006. http://www.nice.org.uk/page.aspx?o=CG033NICEguideline Accessed April 2010.
2. Mazurek G H, Villarino M E; Centers for Disease Control and Prevention. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. MMWR 2003; 52(RR-2): 15-18.
3. Canadian Tuberculosis Committee. Updated recommendations on interferon gamma release assays for latent tuberculosis infection. An Advisory Committee Statement (ACS). CCDR 2008; 34 (ACS-6): 1-13.
4. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149: 177-184.
5. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for diagnosis of latent tuberculosis infection - areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: 340-354.
6. Raby E, Moyo M, Devendra A, et al. The effects of HIV on the sensitivity of a whole blood IFN-γ release assay in Zambian adults with active tuberculosis. PLoS ONE 2008; 3: e2489.
7. Lee J Y, Choi H J, Park I N, et al. Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006; 28: 24-30.
8. Detjen A K, Loebenberg L, Grewal H M S, et al. Short-term reproducibility of a commercial interferon gamma release assay. Clin Vaccine Immunol 2009; 16: 1170-1175.
9. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing report. WHO/HTM/TB/2009.411. Geneva, Switzerland: WHO, 2009.
10. Central Statistical Office, Ministry of Health, Tropical Diseases Research Centre, University of Zambia and Macro International Inc. Zambia demographic and health survey 2007. Calverton, MD, USA: CSO & Macro International Inc, 2009.
11. Ayles H, Sismanidis C, Beyers N, Hayes R, Godfrey-Faussett P. ZAMSTAR, The Zambia South Africa TB and HIV Reduction Study: design of a 2 x 2 factorial community randomized trial. Trials 2008; 9: 63.
12. Cellestis Ltd. QuantiFERON-TB Gold (In-Tube Method) package insert. Carnegie, VIC, Australia: Cellestis Ltd, 2007: Doc 05990301B. http://www.cellestis.com/IRM/Company/ShowPage.aspx?CPID=1255 Accessed April 2010.
13. Pai M, O'Brien R. Serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions? PLoS Med 2007; 4: e208.
14. Veerapathran A, Joshi R, Goswami K, et al. T-cell assays for tuberculosis infection: deriving cut-offs for conversions using reproducibility data. PLoS ONE 2008; 3: e1850.
15. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev Mol Diagn 2006; 6: 413-422.
16. Perry S, Sanchez L, Yang S, Agarwal Z, Hurst P, Parsonnet J. Reproducibility of QuantiFERON-TB Gold In-Tube assay. Clin Vaccine Immunol 2008; 15: 425-432.
17. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: 340-354.
18. Cellestis Ltd. QuantiFERON® TB Gold: precision and reproducibility report. Carnegie, VIC, Australia: Cellestis Ltd, 2007. http://www.cellestis.com/ IRM/Content/Gold/Precisionproductivity.pdf Accessed April 2010.
19. Hang N, Ishizuka N, Keicho N, et al. Quality assessment of an interferon-gamma release assay for tuberculosis infection in a resource-limited setting. BMC Infect Dis 2009; 9: 66.
20. Luetkemeyer A F, Charlebois E D, Flores L L, et al. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med 2007; 175: 737-742.
21. Doherty T M, Demissie A, Menzies D, Andersen P, Rook G, Zumla A. Effect of sample handling on analysis of cytokine responses to Mycobacterium tuberculosis in clinical samples using ELISA, ELISPOT and quantitative PCR. J Immunol Methods 2005; 298: 129-141.
22. Lalvani A, Pareek M. Interferon gamma release assays: principles and practice. Enferm Infecc Microbiol Clin 2010; 28: 245-252.
23. Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen L R, Ravn P. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis-specific interferon-gamma test. Respir Res 2006; 7: 56.
24. Converse P J, Jones S L, Astemborski J, Vlahov D, Graham N M. Comparison of a tuberculin interferon-gamma assay with the tuberculin skin test in high-risk adults: effect of human immunodeficiency virus infection. J Infect Dis 1997; 176: 144-150. (Pubitemid 27272862)